JP2024525959A5 - - Google Patents

Info

Publication number
JP2024525959A5
JP2024525959A5 JP2024504021A JP2024504021A JP2024525959A5 JP 2024525959 A5 JP2024525959 A5 JP 2024525959A5 JP 2024504021 A JP2024504021 A JP 2024504021A JP 2024504021 A JP2024504021 A JP 2024504021A JP 2024525959 A5 JP2024525959 A5 JP 2024525959A5
Authority
JP
Japan
Prior art keywords
peptide
acid sequence
amino acid
pharmaceutical composition
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024504021A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024525959A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/AU2022/050778 external-priority patent/WO2023000038A1/en
Publication of JP2024525959A publication Critical patent/JP2024525959A/ja
Publication of JP2024525959A5 publication Critical patent/JP2024525959A5/ja
Pending legal-status Critical Current

Links

JP2024504021A 2021-07-23 2022-07-22 ランチオニン合成酵素C様タンパク質(LanCL)に結合可能なペプチド組成物およびその使用 Pending JP2024525959A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AU2021902267 2021-07-23
AU2021902267A AU2021902267A0 (en) 2021-07-23 Compositions and uses thereof
PCT/AU2022/050778 WO2023000038A1 (en) 2021-07-23 2022-07-22 Peptide compositions capable of binding lanthionine synthetase c-like protein (lancl) and uses thereof

Publications (2)

Publication Number Publication Date
JP2024525959A JP2024525959A (ja) 2024-07-12
JP2024525959A5 true JP2024525959A5 (enExample) 2025-07-29

Family

ID=84980448

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024504021A Pending JP2024525959A (ja) 2021-07-23 2022-07-22 ランチオニン合成酵素C様タンパク質(LanCL)に結合可能なペプチド組成物およびその使用

Country Status (8)

Country Link
US (1) US20250263435A1 (enExample)
EP (1) EP4373509A4 (enExample)
JP (1) JP2024525959A (enExample)
KR (1) KR20240036634A (enExample)
CN (1) CN117813105A (enExample)
AU (1) AU2022316237A1 (enExample)
CA (1) CA3226259A1 (enExample)
WO (1) WO2023000038A1 (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7751583B2 (ja) * 2019-12-27 2025-10-08 ラテラル、アイピー、プロプライエタリー、リミテッド 環状ペプチド受容体ランチオニンシンテターゼc様タンパク質(lancl)及びその使用

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AUPQ981700A0 (en) * 2000-09-01 2000-09-28 Metabolic Pharmaceuticals Limited Product and method for control of obesity
WO2007068039A1 (en) * 2005-12-12 2007-06-21 Metabolic Pharmaceuticals Limited Treatment of weight gain in estrogen deficient mammals
KR20200075044A (ko) * 2008-01-22 2020-06-25 아라임 파마슈티칼즈, 인크. 조직 손상 관련 질환 및 장애를 예방 및 치료하기 위한 조직 보호 펩티드 및 펩티드 유사체
CN109983137A (zh) * 2016-08-05 2019-07-05 赛拉预测公司 用于预测暴露于孕激素的怀孕女性的早产的生物标志物
EP3585801A4 (en) * 2017-02-22 2021-05-19 Healthtell Inc. PROCEDURES FOR SCREENING INFECTIONS
CN112218650A (zh) * 2018-01-15 2021-01-12 单侧Ip私人有限公司 肽及其用途
EP3671210A1 (en) * 2018-12-21 2020-06-24 Biosystems International KFT Lung cancer protein epitomic biomarkers
JP7751583B2 (ja) * 2019-12-27 2025-10-08 ラテラル、アイピー、プロプライエタリー、リミテッド 環状ペプチド受容体ランチオニンシンテターゼc様タンパク質(lancl)及びその使用
RU2731919C1 (ru) * 2020-03-25 2020-09-09 Федеральное государственное автономное образовательное учреждение высшего образования "Белгородский государственный национальный исследовательский университет" (НИУ "БелГУ") Способ коррекции микроциркуляции в плаценте пептидом, имитирующим альфа-спираль B эритропоэтина, при ADMA-подобной модели преэклампсии
RU2751964C1 (ru) * 2021-02-17 2021-07-21 Федеральное государственное автономное образовательное учреждение высшего образования "Белгородский государственный национальный исследовательский университет" (НИУ "БелГУ") Способ снижения агрегационной способности тромбоцитов

Similar Documents

Publication Publication Date Title
JP2023179436A5 (enExample)
JP2025166834A5 (enExample)
IL262805B2 (en) Agonist agents of cd47 inducing programmed cell death and their use in the treatments of diseases associated with defects in programmed cell death
JP2002523466A5 (enExample)
JP2004525608A5 (enExample)
JP2007535910A5 (enExample)
JP2023541798A5 (enExample)
HRP20240906T1 (hr) Agonisti crf2 receptora i njihova primjena u terapiji
JP2024525959A5 (enExample)
JP2010508030A5 (enExample)
JP2023551122A5 (enExample)
JP2025512515A5 (enExample)
JP2020117504A5 (enExample)
JP2008521795A5 (enExample)
JP2005502332A5 (enExample)
JP2025063151A5 (enExample)
JP2005511038A5 (enExample)
JP2025512749A5 (enExample)
JP2008517998A5 (enExample)
ES2349153T3 (es) Inhibidores del virus de la hepatitis c.
JP2003522185A5 (enExample)
JP2020515283A5 (enExample)
JP2022539560A5 (enExample)
JP2021531246A5 (enExample)
JP2022506044A5 (enExample)